Vanda Pharmaceuticals (VNDA) Misses Q2 EPS by 17c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.32 +1.92%
Financial Fact:
Intangible asset amortization: 2.94M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Intangible asset amortization: 2.94M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($0.46), $0.17 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $52.59 million versus the consensus estimate of $55.1 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2025 revenue of $210-250 million, versus the consensus of $227.7 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- SpaceX (SPCX) gains nearly 6% as traders follow the money
- Goldman Sachs says Fed rate hike unlikely in September
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
